On April 20, 2021, Korean company Huon Labs announced that it will develop a PROLIA biosimilar using PanGen Biotech’s cell culture and purification technology.  PROLIA (denosumab), an Amgen product, is indicated to reduce the risk of facture in patients with osteoporosis with a particular concentration on patients that are postmenopausal women.  The worldwide PROLIA market is expected to grow 3.8% annually (according to Cortellis) from its current worldwide value of $5.13 billion.